Aducanumab-Related Amyloid-Related Imaging Abnormalities
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000004250
Abstract: Abstract When the FDA granted accelerated approval of Biogen's Alzheimer disease drug, aducanumab (marketed as Aduhelm), it deviated from its mission of guaranteeing drug safety and efficacy because the approval was based exclusively on a… read more here.
Keywords: amyloid; aducanumab related; imaging abnormalities; amyloid related ... See more keywords